'Bionanotechnology from Theory to Practice' is a short online, course providing an interdisciplinary and up-to-date overview of the rapidly developing area of bionanotechnology
Page URL: https://www.bionews.org.uk/page_136218

First fetus to be enrolled in stem-cell transplant trial

4 June 2018
Appeared in BioNews 952

The first in utero stem cell transplant trial has welcomed its first baby - born after being treated in the womb with her mother's stem cells.

Elianna Constantino who is now four months old, underwent the in-utero procedure at the University of California, San Francisco's (UCSF's) Benioff Children's Hospital four months before birth. 

Elianna has alpha thalassemia major, a lethal blood disorder that would not have allowed her to survive to term. The diagnosis was made at week 21 of pregnancy, when a fetal ultrasound revealed an enlarged over-pumping heart due to lack of functional red blood cells carrying oxygen to tissues and vital organs. As the fetus's condition was deteriorating quickly, the doctors gave an in utero blood transfusion and the fetus was enrolled in the trial.

The fetus received a further four blood transfusions and an injection of the maternal haemopoietic stem cells through the mother's abdomen and into the umbilical vein in the umbilical cord. The rationale behind the treatment is that that the mother's stem cells will eventually colonise the fetus’s bone marrow and restart the healthy production of red blood cells. Once born, the baby would then be treated for alpha thalassemia major.

Fetuses with alpha thalassemia major usually die before birth due to an overworked, failing heart and severely affected neural and brain development. Current management of the condition involves fetal blood transfusions every 3-4 weeks, which continue for life after birth, or a childhood stem cell transplant from a matched donor.

But multiple transfusions can lead to a dangerous build-up of iron, while childhood transplantation can lead to rejection and an array of side-effects due to the harsh immune-suppression medication.

A maternal stem cell transplant in utero could bypass these issues – the immune system is underdeveloped and idle, while the mother at the time of pregnancy is the ideal match. Dr Tippi MacKenzie, the lead pediatric and fetal surgeon who performed the procedure said that 'everybody has a perfect donor when they're a fetus, and that's the mum'.

However, this phase I clinical trial is assessing the safety rather than the effectiveness of the treatment. Although Elianna survived the pregnancy she is not cured.

Dr MacKenzie acknowledged that 'it is too early to say how effective the stem cell transplantation will be, but we are encouraged by how well she and her mother have tolerated the treatment'. She also said that 'her healthy birth suggests that fetal therapy is a viable option to offer to families with this diagnosis'.

Commonly, women who carry fetuses with alpha thalassemia major opt to terminate their pregnancies due to the poor prognosis and the chance of a live birth. But if this trial shows positive results, such treatment could be extended to treat this and other haematological conditions.

Baby Born in World's First In Utero Stem Cell Transplant Trial
UCSF |  25 May 2018
Five Blood Transfusions, One Bone Marrow Transplant — All Before Birth
New York Times |  25 May 2018
UCSF performs first stem cell transplant in a fetus
Santa Cruz Sentinel |  29 May 2018
27 August 2019 - by Jen Willows 
A new study has shown why stem cell transplants, even derived from the patient's own cells can be rejected...
5 August 2019 - by Rikita Patel 
The US National Institutes of Health has set out new requirements for researchers seeking government grants for human fetal tissue research...
20 May 2019 - by Dr Loredana Guglielmi 
The number of new parents paying to bank their baby's umbilical cord blood for future use in stem cell therapies or transplantation in case of illness has increased by 59 percent in the space of four years in the UK...
9 July 2018 - by Dr Lanay Griessner 
Injecting stem cell-derived cardiac cells after a heart attack may help repair damaged tissue, according to a study published in Nature Biotechnology...
2 July 2018 - by Dr Melanie Krause 
A survey carried out by the blood cancer charity Anthony Nolan has found that 61 percent of British people would not feel encouraged to donate stem cells, even to help a family member or friend...
29 January 2018 - by Emma Laycock 
Scientists in Japan have cultured human trophoblast stem cells, which form the placenta, for the first time...
19 June 2017 - by Cara Foley 
The fetal immune system is more mature in the second trimester than previously thought, which could assist research into diseases, miscarriage and immune tolerance, researchers say...
19 October 2015 - by Dr Jane Currie 
Researchers have announced the first clinical trial of stem-cell therapy for fetuses still in the womb, as a treatment for brittle bone disease...
23 February 2009 - by Dr Will Fletcher 
Neural fetal stem cell injections, administered to a boy in Russia in an attempt to treat a rare genetic condition, have caused benign brain tumours to grow. This is the first documented example of such a complication in a human, although there have been reports of tumours...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.